TPN bag (patient specific), 1660 mL recall — Central Admixture Pharmacy Services, Inc (caps) Los Angeles (Class II)

Central Admixture Pharmacy Services, Inc (caps) Los Angeles is recorded by the U.S. Food and Drug Administration (FDA) as recalling TPN bag (patient specific), 1660 mL — a Class II recall, initiated 2025-12-27 and posted to the FDA enforcement report on 2026-05-13, under recall number D-0524-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “Incorrect Product Formulation: product did not contain insulin as listed in the label.”. From the product description, the form is injection, the strength given is 1660 mL and it is marked Rx only. Distribution is recorded as “CA” — Limited / regional distribution, with the recalling firm on record in CA, United States. It is the only recall number the FDA has filed under event ID 98831. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.

Regulatory snapshot

Recall number D-0524-2026
FDA event ID 98831
Classification Class II (intermediate regulatory tier)
Status Ongoing
Recalling firm Central Admixture Pharmacy Services, Inc (caps) Los Angeles
Recall initiated 2025-12-27
Reported by FDA 2026-05-13
Report lag 137 days from initiation to report
Distribution CA — Limited / regional distribution
Firm location on record CA, United States
Product description (source) TPN bag (patient specific), Rx# 11-4909703-0-1, Compound Volume 1660 mL per bag, Rx only, Single Dose Injection, Refrigerated Injection, Central Admixture Pharmacy Services, Los Angeles, 13128 Imperial Hwy, Santa Fe Spr., CA 90670

Reason reported by FDA

Incorrect Product Formulation: product did not contain insulin as listed in the label.

13 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.

Product identifiers in this record

3 identifying values matched by exact pattern in the 33-word product description above; each is a literal substring of it.

Product named TPN bag (patient specific)
Form Injection
Strength 1660 mL
Marketing category Rx only

Reported in the same month (2026-05)

48 enforcement reports carry a report date in 2026-05; these 8 are the Class II ones nearest this record.

Recall recordRecall numberRecalling firmFDA tierReported
DELFLEX, 1.5%D-0512-2026Fresenius Medical Care Holdings, Inc.Class II2026-05-13
DELFLEX, 2.5%D-0513-2026Fresenius Medical Care Holdings, Inc.Class II2026-05-13
Duloxetine Delayed-Release Capsules, 30 mgD-0514-2026Ajanta Pharma Ltd.Class II2026-05-13
Duloxetine Delayed-Release Capsules, 60 mgD-0515-2026Ajanta Pharma Ltd.Class II2026-05-13
Duloxetine Delayed-Release Capsules, 20 mgD-0516-2026Ajanta Pharma Ltd.Class II2026-05-13
BD PurPrep, 8.3%D-0517-2026Carefusion 213, LLCClass II2026-05-13
BD PurPrep, 8.3%D-0518-2026Carefusion 213, LLCClass II2026-05-13
Octreotide Acetate for Injectable Suspension, 30 mgD-0519-2026Teva Pharmaceuticals Usa, IncClass II2026-05-13

Nearest Class II recalls by date

213 of 250 indexed records share the Class II tier; the 8 nearest to 2026-05-13 by report date are listed here.

Recall recordRecall numberRecalling firmStrength / formReported
Enalapril Maleate Tablets, 20 mgD-0520-2026JB Chemicals And Pharmaceuticals Ltd20 mg · Tablets2026-05-13
Duloxetine Delayed-Release Capsules USP, 60mgD-0522-2026Breckenridge Pharmaceutical, Inc.60mg · Delayed-Release Capsules2026-05-13
NAPROXEN ORAL SUSPENSION, 125 mg/5mLD-0523-2026Acella Pharmaceuticals, LLC125 mg/5mL · Oral Suspension2026-05-13
Systane, 10gD-0491-2026Alcon Research LLC10g · Gel2026-05-06
GenTeal Tears, 10gD-0492-2026Alcon Research LLC10g · Gel2026-05-06
Optase Dry Eye Intense Drops (Glycerin 0.2%)D-0499-2026Scope Health0.2% · Drops2026-05-06
iVIZIA, 0.5%D-0500-2026Thea Pharma, Inc.0.5% · Eye Drops2026-05-06
Similasan, 0.5%D-0501-2026Thea Pharma, Inc.0.5% · Eye Drops2026-05-06

Reading this record

Class II is the FDA's own severity tier for the recall action — 213 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual.

Namespace context: the Class II index (213 records) and the recall hub (250 records, 118 FDA events); Central Admixture Pharmacy Services, Inc (caps) Los Angeles (1 indexed records) aggregates this firm across datasets.

Coverage and limits of this record

This page reflects the openFDA enforcement report for D-0524-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.

Source & provenance

Official source
https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0524-2026%22
Source dataset
openFDA Drug Enforcement API
Publication date
2026-05-13
Ingested
2026-08-22
Record hash
99b7035e92d5078b

Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.